A product of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), VEC-162 is a balanced melatonin receptor agonist for transient insomnia.
The company’s Phase III clinical trail evaluating VEC-162 in transient insomnia yielded top line positive results.
VEC-162 demonstrated statistically significant improvements at all three tested doses compared to placebo (p<0.001) in the primary endpoint of the trial, Latency to Persistent Sleep (LPS), a measure of sleep onset.
VEC-162 also produced statistically significant improvements relative to placebo in Latency to Non-Awake (LNA), another measure of sleep onset, Wake After Sleep Onset (WASO), a measure of sleep maintenance, and Total Sleep Time (TST).
VEC-162 was found to be safe and well tolerated in the said randomized, double-blind, placebo-controlled, multi-center study of 412 adults in a sleep laboratory setting.
Find more details from Vanda Pharma’s press release.
[Photo Credit: www.bbc.co.uk]
.jpg)
Comment Preview